Direct oral anticoagulants (DOACs) have changed the management of venous thromboembolism (VTE). In recent years their use has extended to the realm of cancer-associated VTE (CAT), but experts warn that a paucity of trial data in that setting should breed caution in the care of patients with haematological malignancies. “Given the escalated risk of VTE ...
Cancer‐associated VTE: caution urged for DOACs in haematological malignancies
By Dave Levitan
4 Mar 2021